Navigation Links
Bioheart, Inc. Announces Additional Funding Support
Date:8/21/2008

E mark approval for marketing throughout Europe.

-- On July 10, 2008 the Company announced that it secured worldwide non-exclusive distribution rights to the Bioheart 3370 Heart Failure Monitor, an interactive and simple-to-use at-home intelligent device designed specifically to improve available healthcare to patients outside hospitals who are suffering from heart failure. The device, manufactured by RTX Healthcare A/S (Denmark), has 510(k) market clearance from the U.S. Food and Drug Administration for marketing in the U.S. and CE mark approval for marketing in Europe and other countries that follow this mark.

About Bioheart, Inc.:

Bioheart, Inc. (Nasdaq: BHRT) is committed to delivering intelligent devices and biologics that help monitor, diagnose and treat heart failure and cardiovascular diseases. Its goals are to improve a patient's quality of life and reduce health care costs and hospitalizations. Specific to biotechnology, Bioheart is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. Its lead product candidate, MyoCell(R), is an innovative clinical muscle-derived stem cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. The Company's pipeline includes multiple product candidates for the treatment of heart damage, including Bioheart Acute Cell Therapy, an autologous, adipose tissue-derived stem cell treatment for acute heart damage, and MyoCell(R) SDF-1, a therapy utilizing autologous cells that are genetically modified to express additional potentially therapeutic
'/>"/>

SOURCE Bioheart, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Bioheart, Inc. to Present at Red Chip Investor Conference in New York
2. Bioheart, Inc., Announces Letter of Intent to Acquire MEDICALGORITHMICS, Ltd.
3. Bioheart, Inc. Announces Financial Results for Second Quarter 2008
4. Bioheart, Inc. Announces Results of Annual Meeting
5. Bioheart, Inc., Announces Management Change
6. Bioheart, Inc. to Introduce At-Home Heart Failure Monitor for Congestive Heart Failure Patients
7. Bioheart, Inc., Board Appoints Howard J. Leonhardt Chief Executive Officer
8. Bioheart, Inc., Added to Russell Microcap Index
9. Bioheart, Inc. to Transfer to Nasdaq Capital Market
10. Bioheart, Inc. to Host Annual Meeting of Shareholders on Wednesday, July 30, 2008
11. Bioheart, Inc. Reports Receipt of Notification from NASDAQ Regarding Non-Compliance with Continued Listing Requirements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... , July 31, 2015 China Cord ... China,s leading provider of cord blood ... cell storage services, today announced that the Company has ... U.S. Securities and Exchange Commission. The filed Form 20-F ... March 31, 2015. The Form 20-F can be accessed ...
(Date:7/30/2015)...   GenoSpace , a leading provider of ... of genomic and other biomedical data, today announced ... company as Vice President of Sales and Marketing. ... "GenoSpace partners with its customers to ... explore complex sets of genomic, phenotypic and other ...
(Date:7/30/2015)... Diego , CA (PRWEB) , ... July 30, ... ... announced the successful completion of a field clinical study of its canine osteoarthritis ... developed together with Aratana Therapeutics (Kansas City, KS) and will be marketed in ...
(Date:7/30/2015)... 2015 Ascendis Pharma A/S (Nasdaq: ... innovative TransCon technology to address significant unmet medical ... six-month Phase 2 study to evaluate the safety ... 53 treatment-naïve, pre-pubertal children with growth hormone deficiency, ... with the top-line results from our Phase 2 ...
Breaking Biology Technology:China Cord Blood Corporation Files Its Annual Report on Form 20-F 2GenoSpace Introduces Matthew Fischer as Vice President of Sales and Marketing 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7
... Study Published in the Journal of Clinical Oncology Proves Accurate, ... ... Reaction (RT-PCR), REDWOOD CITY, Calif., June 2 Genomic ... of Clinical Oncology,(JCO) published results of a study confirming RT-PCR ...
... AKIVA, Israel, June 2 ITGI Medical, Ltd.,(TASE: ITGI) ... certified,Over and Under(R) Pericardium Covered Stent (PCS) in the ... covered with a heterologous tissue,designed to set a barrier ... is intended for situations such as degenerated Saphenous Vein,Graft ...
... Perceptive Informatics, the,technology subsidiary of PAREXEL International ... it has integrated its leading medical imaging,technology ... image,management and reporting system provided by Digisonics, ... assessment in clinical studies.,The system provides high-performance ...
Cached Biology Technology:Genomic Health Announces Expansion of Oncotype DX(R) Breast Cancer Test to Include Quantitative Estrogen Receptor (ER) and Progesterone Receptor (PR) Scores 2Genomic Health Announces Expansion of Oncotype DX(R) Breast Cancer Test to Include Quantitative Estrogen Receptor (ER) and Progesterone Receptor (PR) Scores 3Genomic Health Announces Expansion of Oncotype DX(R) Breast Cancer Test to Include Quantitative Estrogen Receptor (ER) and Progesterone Receptor (PR) Scores 4Over and Under(R) Pericardium Covered Stent is now in use in England and Proves Great Deliverability 2Perceptive Informatics Enhances Medical Imaging Capabilities for Assessment of Cardiac Function 2Perceptive Informatics Enhances Medical Imaging Capabilities for Assessment of Cardiac Function 3Perceptive Informatics Enhances Medical Imaging Capabilities for Assessment of Cardiac Function 4
(Date:7/31/2015)... de 2015 La 10 th International Conference ... de BGI del 22 al 25 de octubre de 2015 en ... año, la conferencia celebra su décimo aniversario. Desde su inauguración ... de las reuniones anuales más influyentes del mundo en el ... dinámicas, entusiastas y mejores a nivel científico. ...
(Date:7/30/2015)... 2015 Cellecta, Inc., a U.S.-based provider ... and biomarker discovery, announced the release of its ... all human protein coding genes. CRISPR technology enables ... gene,s function. Cellecta,s new Human Whole Genome CRISPR ... so that researchers can investigate in a single ...
(Date:7/23/2015)... Research and Markets ( http://www.researchandmarkets.com/research/rzzp3v/global_outlook_of ) ... Outlook of the Biometrics Industry 2015 " ... global biometrics market is likely to witness significant ... to the uptake of multiple technologies available. The ... the growth of biometrics in existing applications as ...
Breaking Biology News(10 mins):La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3
... streams and rivers, affecting the number and variety of some ... found. , Rivers and streams are key ecosystems for ... yet little emphasis has been given so far to the ... , Now a twenty-five year study at Llyn Brianne ...
... must prevent the immune system from launching an all-out ... a nutrient "floodgate" that serves to protect against such ... May 4, 2007 issue of the journal Cell, a ... animals lacking a protein enriched in fat cells, called ...
... University of Manchester researchers are ridding diabetic patients of ... with maggots. , Professor Andrew Boulton and his team ... patients whose foot ulcers were contaminated with MRSA and ... period of three weeks, much quicker than the 28-week ...
Cached Biology News:Keeping the immune system from starting a 'food fight' 2Maggots rid patients of MRSA 2
... Assay is an anchorage-independent growth assay in ... stringent assay for detecting malignant transformation of ... with carcinogens or carcinogen inhibitors) are cultured ... for 21-28 days. Following this incubation ...
The Saturn 2200 answers your GC/MS questions with the CP-3800 GC and the 2000 Series Ion Trap MS! These components create a platform for the worlds most versatile GC and flexible MS. Both deliver une...
... Kit uses a simplified procedure and streamlines ... The kit is based on the three ... and sodium bisulfite where cytosine is converted ... innovative in-column desulphonation reaction eliminates several precipitation ...
... Invitrogen makes blotting of E-PAGE Gels easier ... fiber blotting pad and several types of ... fit 8.6 cm x 13.5 cm E-PAGE ... membranes are designed for western transfer of ...
Biology Products: